Malignant Pleural Mesothelioma: Update on Treatment Options with a Focus on Novel Therapies

Clinics in Chest Medicine

Volumn 34, Issue 1, 2013, Pages 99-111

  Haas, Andrew R ^a   Sterman, Daniel H ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chemotherapy; Gene therapy; Malignant pleural mesothelioma; Multimodal therapy; Radiation therapy

Indexed keywords

ADENOVIRUS VECTOR; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; BETA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GAMMA INTERFERON; GANCICLOVIR; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERLEUKIN 12; INTERLEUKIN 2; NAVELBINE; PEMETREXED; PLACEBO; PROTEIN P53; RALTITREXED; SCH 721015; TETRATHIOMOLYBDIC ACID; THALIDOMIDE; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CATHETER INFECTION; CONTINUOUS INFUSION; CYTOKINE RELEASE SYNDROME; DYSPNEA; FLU LIKE SYNDROME; HEART TAMPONADE; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOTENSION; INTENSITY MODULATED RADIATION THERAPY; LUNG RESECTION; LYMPHOCYTOPENIA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURODESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SUICIDE GENE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; MESOTHELIOMA; MOLECULAR TARGETED THERAPY; PLEURAL NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84873597168     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2012.12.005     Document Type: Review

References (84)

1. Antman K.H., Pass H.I., Li F.P., et al. Benign and malignant mesothelioma, cancer. Principles and practice of oncology 1993, 1489-1508. J.B. Lippincott Company, Philadelphia, PA. 4th edition. V.T. DeVita, S. Hellman, S. Rosenberg (Eds.).
2. Antman K.H. Natural history and epidemiology of malignant mesothelioma. Chest 1993, 103:373S.
3. Pisani R.J., Colby T.V., Williams D.E. Malignant mesothelioma of the pleura. Mayo Clin Proc 1988, 63:1234.
4. Robinson B.W., Lake R.A. Advances in malignant mesothelioma. N Engl J Med 2005, 353:1591-1603.
5. Peto J., Hodgson J.T., Matthews F.E., et al. Continuing increase in mesothelioma mortality in Britain. Lancet 1995, 345:535.
6. British Thoracic Society Standards of Care Committee Statement on malignant mesothelioma in the United Kingdom. Thorax 2001, 56:250.
7. Sterman D.H., Kaiser L.R., Albelda S.M. Advances in the treatment of malignant pleural mesothelioma. Chest 1999, 116:504-520.
8. Sterman D.H., Albelda S.M. Advances in the diagnosis, evaluation and management of malignant pleural mesothelioma. Respirology 2005, 10:266-283.
9. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
10. Haas A.R., Sterman D.H., Musani A.I. Malignant pleural effusions: management options with consideration of coding, billing, and a decision approach. Chest 2007, 132(3):1036-1041.
11. Pien G.W., Gant M., Washam C., et al. Use of an implantable pleural catheter for "trapped lung" syndrome in patients with malignant pleural effusion. Chest 2001, 119:1641-1646.
12. Lee Y.C., Fysh E.T. Indwelling pleural catheter: changing the paradigm of malignant effusion management. J Thorac Oncol 2011, 6(4):655-657.
13. Davies H.E., Mishra E.K., Kahan B.C., et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012, 307(22):2383-2389.
14. Waller D.A., Morritt G.N., Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest 1995, 107:1454.
15. van Ruth S., Baas P., Zoetmulder F.A. Surgical treatment of malignant pleural mesothelioma: a review. Chest 2003, 123:551.
16. Rusch V.W., Piantadosi S., Holmes E.C. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991, 102:1.
17. Sugarbaker D.J. Extrapleural pneumonectomy, chemotherapy and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991, 102:10.
18. Grondin S.C., Sugarbaker D.J. Pleuropneumonectomy in the treatment of malignant pleural mesothelioma. Chest 1999, 116:450S.
19. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54.
20. Maggi G., Casadi C., Cianci R., et al. Trimodality management of malignant pleural mesothelioma. Eur J CardioThorac Surg 2001, 19:346.
21. Sugarbaker D.J. Multimodality management of malignant pleural mesothelioma: introduction. Semin Thorac Cardiovasc Surg 2009, 21(2):95-96.
22. Chang M.Y., Sugarbaker D.J. Innovative therapies: intraoperative intracavitary chemotherapy. Thorac Surg Clin 2004, 14(4):549-556.
23. Tilleman T.R., Richards W.G., Zellos L., et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 2009, 138(2):405-411.
24. Bölükbas S., Manegold C., Eberlein M., et al. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer 2011, 71:75-81.
25. Pass H.I., Temeck B.K., Kranda K., et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997, 4:628-633.
26. Friedberg J.S., Mick R., Stevenson J., et al. A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg 2003, 75:952-959.
27. Friedberg J.S., Culligan M.J., Mick R., et al. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg 2012, 93(5):1658-1665. [discussion: 1665-7].
28. Lang-Lazdunski L., Bille A., Belcher E., et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2011, 6(10):1746-1752.
29. Bölükbas S., Eberlein M., Schirren J. Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma. J Thorac Oncol 2012, 7(5):900-905.
30. de Graaf-Strukowska L., van der Zee J., van Putten W., et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura-a single institution experience with 189 patients. Int J Radiat Oncol Biol Phys 1999, 43:511.
31. Boutin C., Rey F., Viallat J.R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. Chest 1995, 108:754.
32. Bydder S., Phillips M., Joseph D.J., et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 2004, 91:9.
33. Ahamad A., Stevens C., Smythe R., et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2003, 55:768.
34. Ahamad A., Stevens C., Smythe R., et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMTR) to the chest. Cancer J 2003, 9:476.
35. Allen A.M., Czerminska M., Jänne P.A., et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006, 65(3):640-645.
36. Janne P.A. Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer 2003, 5:98-106.
37. van Meerbeeck J.P., Gaafar R., Manegold C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23:6881-6889.
38. Lee C.W., Murray N., Anderson H., et al. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 2009, 64:308-313.
39. Ceresoli G.L., Zucali P.A., Favaretto A.G., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006, 24:1443-1448.
40. Favaretto A.G., Aversa S.M., Paccagnella A., et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003, 97:2791-2797.
41. Kindler H.L., Karrison T.G., Gandara D.R., et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo inpatients with malignant mesothelioma. J Clin Oncol 2012, 30(20):2509-2515.
42. Zucali P.A., Ceresoli G.L., Garassino I., et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008, 112(7):1555-1561.
43. Xanthopoulos A., Bauer T.T., Blum T.G., et al. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol 2008, 3:34.
44. Stebbing J., Powles T., McPherson K., et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009, 63:94-97.
45. Pasello G., Nicotra S., Marulli G., et al. Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience. Lung Cancer 2011, 73(3):351-355.
46. Ceresoli G.L., Zucali P.A., De Vincenzo F., et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011, 72:73-77.
47. Zauderer M.G., Krug L.M. Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Canc Netw 2012, 10(1):42-47.
48. Mathy A., Baas P., Dalesio O., et al. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005, 50:83.
49. Porta C., Mutti L., Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007, 59:149.
50. Govindan R., Kratzke R.A., Herndon J.E., et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005, 11:2300.
51. Garland L.L., Rankin C., Gandara D.R., et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007, 25:2406.
52. Baas P., Boogerd W., Dalesio O., et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005, 48:291.
53. Dubey S., Janne P.A., Krug L., et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol 2010, 5:1655-1661.
54. Ike O., Shimuzu V., Hitomi S., et al. Treatment of malignant pleural effusions with doxorubicin hydrochloride-containing ply (L-lactic acid) microspheres. Chest 1991, 99:911.
55. Monneuse O., Beaujard A.C., Guibert B., et al. Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies. Br J Cancer 2003, 88:1839.
56. van Ruth S., Baas P., Haas R.L., et al. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 2003, 10:176.
57. Bone G. Postoperative empyema and survival in lung cancer. Br Med J 1973, 2(5859):178.
58. Minasian H., Lewis C.T., Evans S.J. Influence of postoperative empyema on survival after pulmonary resection for bronchogenic carcinoma. Br Med J 1978, 2(6148):1329-1331.
59. Lawaetz O., Halkier E. The relationship between postoperative empyema and long-term survival after pneumonectomy. Results of surgical treatment of bronchogenic carcinoma. Scand J Thorac Cardiovasc Surg 1980, 14(1):113-117.
60. Bakker W., Nijhuis-Heddes J.M., van der Velde E.A. Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report. Cancer Immunol Immunother 1986, 22(2):155-159.
61. Robinson B.W., Manning L.S., Bowman R.V., et al. The scientific basis for the immunotherapy of human malignant mesothelioma. Eur Respir Rev 1993, 3:195.
62. Astoul P., Picat-Joossen D., Viallat J.R., et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 1998, 83:2099.
63. Boutin C., Nussbaum E., Monnet I., et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant mesothelioma. Cancer 1994, 74:2460.
64. Boutin C., Viallat J.R., Van Zandwijk N., et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991, 67:2033.
65. Goey S.H., Eggermont A.M., Punt C.J., et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 1995, 72:1283.
66. Nowak A.K., Lake R.A., Kindler H.L., et al. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002, 29:82.
67. Davidson J.A., Musk A.W., Wood B.R., et al. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J Immunother 1998, 21(5):389-398.
68. Vachani A., Moon E., Wakeam E., et al. Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol 2010, 42(4):385-393.
69. Robinson B.W., Mukherjee S.A., Davidson A., et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 1998, 21:211.
70. Hwang H.C., Smythe W.R., Elshami A.A., et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995, 13:7.
71. Smythe W.R., Hwang H.C., Amin K.M., et al. Successful treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex-thymidine kinase gene. Ann Surg 1995, 222:78.
72. Sterman D., Treat J., Litzky L.A., et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998, 9:1083.
73. Sterman D.H., Molnar-Kimber K., Iyengar T., et al. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther 2000, 7:1511.
74. Sterman D.H., Recio A., Vachani A., et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005, 11(20):7444-7453.
75. Schwarzenberger P., Lei D.H., Freeman S.M., et al. Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma. Am J Respir Cell Mol Biol 1998, 19:333.
76. Schwarzenberger P., Byrne P., Gaumer R., et al. Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study. Cancer Gene Ther 2011, 18(12):906-912.
77. Mukherjee S., Haenel T., Himbeck R., et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther 2000, 7:663.
78. Odaka M., Sterman D., Wiewrodt R., et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy due to induction of systemic immunity. Cancer Res 2001, 61:6201-6212.
79. Vachani A., Sterman D.H., Albelda S.M. Cytokine gene therapy for malignant pleural mesothelioma. J Thorac Oncol 2007, 2(4):265-267.
80. Sterman D.H., Recio A., Carroll R.G., et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007, 13:4456-4466.
81. Sterman D.H., Recio A., Haas A.R., et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010, 18(4):852-860.
82. Sterman D.H., Haas A.R., Moon E., et al. A trial of intrapleural adenoviral-mediated interferon-alpha2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 2011, 184:1395-1399.
83. Zhao Y., Moon E., Carpenito C., et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediated regression of human disseminated tumor. Cancer Res 2010, 70(22):9053-9061.
84. Dong M., Li X., Hong L.J., et al. Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin. J Int Med Res 2008, 36:1273-1278.